Table 2.

Notification rate and incidence of AEFIs among the study population during 2009/2010 inflenza pandemic and 2014/2015 influenza season.

Study period	2009/2010 inflenza pandemic								2014/2015 influenza season
Type of AEFI surveillance	National pharmacovigilance survey				Spontaneous reporting				Spontaneous reporting
	No. of vaccinated subjects	No. of subjects reporting AEFIs	Incidence rate (%)	95% CI (%)	No. of vaccinated subjects	No. of subjects reporting AEFIs	Notification rate (/10,000 subjects)	95% CI (/10,000)	No. of vaccinated subjects	No. of subjects reporting AEFIs	Notification rate (/10,000 subjects)	95% CI (/10,000)
Health professionals	400	350	87.5	84.3–90.7	9874	39	39.5	27.1–51.9	17,186	–	–	–
Health students	–	–	–	–	–	–	–		4871	–	–	–
Pilgrims	–	–	–	–	39,206	2	0.5	0.0–1.2	–	–	–	–
Subjects with diabetes or respiratory diseases	449	300	66.8	62.5–71.2	221,730	104	4.7	3.8–5.6	37,761	–	–	–
Subjects with other chronic diseases	77	38	49.4	38.2–60.5	222,536	22	1.0	0.6–1.4	–	–	–	–
Pregnant women	67	36	53.7	41.8–65.7	167,870	3	0.2	0.0–0.4	–	–	–	–
Children 6–23 months	20	4	20.0	2.5–37.5	11,658	–	–		–	–	–	–
Elderly people in close institutions	–	–	–	–	–	–	–		5200	–	–	–
Subjects working in close institutions	–	–	–	–	6932	–	–		–	–	–	–
Healthy subjects	68	43	63.2	51.8–74.7	26,077	14	5.3	2.6–8.2	–	–	–	–
Not specified	–	–	–	–	–	38	–		–	–	–	–
Total (*)	1000	771	77.1	74.5–79.7	705,883	222	3.1	2.7–3.6	65,018	8	1.2	0.4 - 2.1

AEFI, adverse events following immunization.

(*) The difference between the two (spontaneous) notification rates of AEFI is statistically significant (Fisher’s exact test = 0.002).